BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
SUBSCRIBE
BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
BullScope
No Result
View All Result
Home Bargains & Bubbles

ExxonMobil: A Machine That Prints Cash While the Market Argues About the Price Tag

Moe Alsumidaie by Moe Alsumidaie
August 28, 2026
in Bargains & Bubbles
0
74
SHARES
1.2k
VIEWS
Share on XShare on LinkedInShare on Facebook

The heart of it

ExxonMobil’s filed numbers show a company generating more free cash in a single quarter than most S&P 500 firms earn in a year. The stock has climbed sharply over the past twelve months, yet it sits nearly 9% below its fifty-two-week high, and the analyst community is split almost evenly between “buy” and “hold.” The math says the cash machine is running at full speed. The mood, meaning what the market is currently willing to pay, says it isn’t sure that speed is sustainable. That gap is the story.

How a dinosaur became a cash engine

A decade ago, ExxonMobil was the company everyone loved to criticize: slow, bureaucratic, wedded to oil while the world talked about solar panels. It lost its AAA credit rating in 2016 after crude prices collapsed. It cut exploration budgets so deeply that some analysts questioned whether it could replace the oil it was pumping. Then came a sequence of moves that rewrote the story. The company doubled down on the Permian Basin in West Texas, the shale formation that turned American oil production upside down. It bought Pioneer Natural Resources in October 2023 in an all-stock deal worth roughly $60 billion, the largest oil acquisition in a generation, and swallowed Pioneer’s low-cost Permian acreage whole.

The bet paid off faster than almost anyone expected. By the second quarter of 2026, the Permian alone was producing a record 1.8 million barrels of oil equivalent every single day, according to the Q2 2026 earnings release. That is more oil than most OPEC members pump. The question now is not whether the machine works. It is whether the price tag on the machine is fair.

What the filings actually say

The 10-Q filed for the quarter ended June 30, 2026 is the kind of document that makes a finance professor sit up straight. Net income attributable to ExxonMobil reached $18.7 billion for the first six months of 2026 alone. To put that in household terms: if a family earned $18,700 in six months, they’d consider that a decent year. ExxonMobil earned the equivalent of that, per billion dollars of scale, in half a year.

BullScope TerminalWant the full evidence sheet behind pieces like this?The terminal runs the complete workup: ExxonMobil and 500+ other names, on the same official data.See the evidence engine →

Free cash flow, which is the money left over after the company pays for all its drilling and building, came in at $17.2 billion for Q2 2026 alone. That single quarter’s surplus is larger than the entire annual revenue of many well-known American companies. The company is not borrowing to fund its ambitions: the net debt-to-capital ratio, a measure of how much of the business is financed by borrowing rather than by its own earnings, sits at a conservative 10.7%. Think of it as a homeowner who owns nearly ninety cents of every dollar of their house’s value outright.

Crude prices helped. Brent crude averaged nearly $97 a barrel in Q2 2026, up sharply from the prior quarter, partly because geopolitical tensions in the Middle East tightened supply. ExxonMobil’s refining business, which turns crude oil into gasoline and jet fuel, swung from a meaningful loss in Q1 to a substantial profit in Q2, as global refining margins hit near-record levels. Both tailwinds, high crude and wide refining margins, are real. Both can also reverse.

For a saver trying to understand whether this business is durable, the reserve picture matters as much as the quarterly profit. The 2025 annual report filed in February 2026 shows proved reserves large enough, at current production rates, to keep the company running for about eleven years without finding another drop. That is a long runway, though external analysis from GuruFocus flags a reserve replacement ratio near zero as of mid-2026, meaning the company has not yet demonstrated it is finding new oil as fast as it pumps the old. Management would point to Guyana and the Permian as the answer; the data does not yet fully confirm it.

Returning money faster than it can spend it

Here is the detail that tends to surprise people: ExxonMobil is buying back its own shares at a pace of $20 billion a year in 2026, while also paying a quarterly dividend of $1.03 per share, part of more than four decades of consecutive dividend increases. In Q2 alone, the company returned more than $9 billion to shareholders through dividends and repurchases combined. That is roughly $100 million every single day, flowing back to the people who own the stock.

Buybacks matter because they shrink the number of shares outstanding, meaning each remaining share owns a slightly larger slice of the same business. A household analogy: if five siblings own a pizza equally and one sells their slice back to the group, the remaining four each own a bigger piece without the pizza getting any larger. Whether that is the best use of capital depends entirely on whether the stock is cheap or expensive, which is precisely what the market is debating right now.

BullScope TerminalYou just read ExxonMobil’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →

What the market is paying, and why it hesitates

At a recent price just above $156, the stock has gained sharply over the past twelve months, a remarkable run for a company of this size. Yet it sits about 9% below its fifty-two-week high, a signal that the momentum has stalled. MarketBeat’s August 2026 consensus shows the analyst community roughly split, with average price targets clustering in the low-to-mid $160s. Barclays and Morgan Stanley both carry bullish targets with buy ratings, per Zacks. DZ Bank moved to hold in early August, essentially saying the stock is already fairly priced.

The hesitation has a logic. ExxonMobil narrowly missed Q2 earnings estimates, according to BNN Bloomberg, partly because of production outages tied to Middle East disruptions. The company is also spending heavily: capital expenditures are guided at $27 billion to $29 billion for 2026, rising further through 2030. That is a large and sustained bet on oil prices staying high enough to justify the drilling. If crude retreats meaningfully, the math changes materially.

The energy transition spending, roughly $20 billion in lower-emission investments across the second half of the decade, is real but early-stage. Management projects those businesses could generate over a billion dollars in annual earnings by 2030 and a multiple of that by 2040. Those are long time horizons with wide uncertainty bands, and the data cannot yet confirm them.

For anyone weighing this business against its price, the central question is whether the current oil price environment, and the refining margins that come with it, represent a new normal or a temporary peak. The filed numbers show a company performing at a very high level right now. Whether the market’s current price already captures that performance, or underestimates it, is a question the math alone cannot settle.

Reading the numbers

  • $18.7 billion net income, first half of 2026 (from the 10-Q, June 30, 2026): this is profit after every cost is paid. It means the business kept roughly $1 of every $4 it brought in. A corner bakery keeping 25 cents of every dollar would be considered exceptional.
  • $17.2 billion free cash flow, Q2 2026 alone (from the Q2 press release): free cash flow is what remains after paying for all capital spending. It is the money the company can actually distribute or save. One quarter’s surplus here exceeds the full-year revenue of many large American businesses.
  • 10.7% net debt-to-capital ratio (from the 10-Q, June 30, 2026): for every dollar of the company’s total value, about eleven cents is borrowed. That is a conservative level for an industrial company of this scale, leaving room to borrow more if a downturn hits.
  • 11.2-year reserve life index (from the 2025 annual report): at current production rates, proved reserves last about eleven years. A household analogy: a pantry stocked for eleven years of meals. Comfortable, but only if the family keeps shopping.
  • $20 billion annual buyback pace, 2026 (Q2 press release): the company is spending roughly $55 million every day repurchasing its own shares. If the stock is undervalued, this accelerates value for remaining holders. If it is fairly valued or expensive, it is a less efficient use of cash, and the data cannot resolve which is true.

Sources

  • ExxonMobil 10-Q, quarter ended June 30, 2026, SEC EDGAR
  • ExxonMobil Q2 2026 earnings press release, investor.exxonmobil.com
  • ExxonMobil 2025 10-K annual report, StockTitan
  • ExxonMobil Q2 2026: record margins, Middle East disruption, Investing.com
  • ExxonMobil misses Q2 profit estimates, BNN Bloomberg, July 31, 2026
  • U.S. firms post sharp Q2 2026 earnings gains, Oil & Gas Journal
  • ExxonMobil analyst consensus, MarketBeat, August 6, 2026
  • ExxonMobil price targets, Zacks
  • ExxonMobil reserve replacement ratio, GuruFocus
  • ExxonMobil acquisitions including Pioneer, Tracxn
  • ExxonMobil dividend history, StockAnalysis
BullScope publishes impersonal research for a general audience. Nothing here is personalized investment advice, and nothing here is a recommendation to buy or sell any security. As of publication, neither BullScope nor its operator holds a position in any security, covered or otherwise; we do not trade at all, and we accept no compensation from any company we cover. When a conflict of interest exists, we do not publish: companies that compensate our operator in any capacity, or about which our operator could hold nonpublic information, are barred from coverage automatically, as described in the conflicts policy in our methodology. Figures come from company filings and public data through our published methodology; forecasts are conditional scenarios, not predictions and not promises. Markets carry risk, including loss of principal. Consider your own situation, or consult a licensed adviser, before acting on anything you read.
BullScope TerminalYou just read ExxonMobil’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →
Moe Alsumidaie

Moe Alsumidaie

Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.

Recommended For You

Abbott’s Split Personality: Revenue Climbs 14%, the Stock Falls Anyway

by Moe Alsumidaie
October 22, 2026
0

Abbott Laboratories spent most of the pandemic era as a Wall Street darling, its COVID test sales turning a steady healthcare conglomerate into a growth story. Then the...

Read moreDetails

The $14 Acquisition Price and the Arbitrage Gap the Market Is Pricing

by Moe Alsumidaie
October 16, 2026
0

The short version Sun Pharmaceutical agreed in April 2026 to buy Organon for $14.00 a share in cash, a deal Organon shareholders approved in July. The stock trades...

Read moreDetails

From $8 to $0.45: Ascend Wellness Is Generating Real Cash While the Market Prices It for Failure

by Moe Alsumidaie
October 14, 2026
0

The story, briefly The math, meaning what the filed numbers actually show, tells a story of a cannabis retailer that turned cash-flow positive in 2023 and has been...

Read moreDetails

ADMA Biologics: A Business Earning Real Money, Priced Like It Might Not

by Moe Alsumidaie
October 13, 2026
0

Six years ago, ADMA Biologics was losing nearly two dollars for every dollar it brought in. The company made a single class of medicine, plasma-derived immunoglobulins (proteins collected...

Read moreDetails

Viatris: The Stock Has Run 72% in a Year. The Filed Numbers Tell a More Complicated Story.

by Moe Alsumidaie
October 9, 2026
0

The share price is up 72% over the past twelve months. Revenue has fallen every single year since 2021. Those two facts belong to the same company, and...

Read moreDetails
Next Post

Evidence Sheet: ExxonMobil Holdings (XOM)

Please login to join discussion
BullScope
The Research Terminal
Run any stock through the BullScope evidence engine. Filings in, evidence out. Every number explains itself.
Open the Terminal
A BullScope product

Related News

The Grocery Giant’s Quiet Reinvention: What Walmart’s Filed Numbers Say About the American Consumer

August 3, 2026

The Margin That Wasn’t Supposed to Exist

August 4, 2026

Regeneron’s Claims Ledger: What Management Said, What the Filings Show, and What October 30 Will Settle

October 8, 2026
BullScope

BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.

Prefer BullScope.ai on Google

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

No Result
View All Result
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.